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Human replication protein A (RPA), composed of RPA70,
RPA32, and RPA14 subunits, undergoes hyperphosphorylation in
cells in response to DNA damage. Hyperphosphorylation that
occurs predominately in the N-terminal region of RPA32 is believed
to play a role in modulating the cellular activities of RPA essential
for almost all DNA metabolic pathways. To understand how the
hyperphosphorylation modulates the functions of RPA, we compared the structural characteristics of full-length native and hyperphosphorylated RPAs using mass spectrometric protein footprinting, fluorescence spectroscopy, and limited proteolysis. Our mass
spectrometric data showed that of 24 lysines and 18 arginines
readily susceptible to small chemical reagent modification in native
RPA, the three residues Lys-343, Arg-335, and Arg-382, located in
DNA binding domain B (DBD-B) of RPA70, were significantly
shielded in the hyperphosphorylated protein. Tryptophan fluorescence studies indicated significant quenching of Trp-361, located in
the DBD-B domain, induced by hyperphosphorylation of RPA.
Consistently, DBD-B became more resistant to the limited proteolysis by chymotrypsin after RPA hyperphosphorylation. Taken
together, our results indicate that upon hyperphosphorylation of
RPA32 N terminus (RPA32N), RPA undergoes a conformational
change involving the single-stranded DNA binding cleft of DBD-B.
Comparison of the interactions of native and hyperphosphorylated
RPAs with short single-stranded oligonucleotides or partial DNA
duplexes with a short 5ⴕ or 3ⴕ single-stranded DNA tails showed
reduced affinity for the latter protein. We propose that the hyperphosphorylation may play a role in modulating the cellular pathways by altering the DBD-B-mediated RPA-DNA and RPA-protein
interactions, hypothetically via the interaction of hyperphosphorylated RPA32N with DBD-B.

Replication protein A (RPA)2 is a eukaryotic single-stranded DNA
(ssDNA)-binding protein essential for DNA replication, repair, recom-
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bination (1–3), and cellular DNA-damage checkpoints (4, 5). RPA is
composed of three subunits, RPA70, RPA32, and RPA14, named after
their molecular masses of 70, 32, and 14 kDa, respectively. Although the
structure of full-length RPA trimer remains unsolved, x-ray crystallography, NMR, and biochemical studies reveal that RPA70 contains four
domains, the N-terminal domain of RPA70 and DNA binding domains
(DBDs) A, B, and C (6 – 8). The tandem DBD-A and DBD-B harbor the
major ssDNA binding activity of RPA heterotrimer (9). DBD-C has a
conserved zinc finger (10) and exhibits low affinity for ssDNA but interacts with the other two subunits to form a RPA trimerization core (11).
RPA32 consists of three domains, including an unstructured N-terminal phosphorylation domain (RPA32N), a central DNA binding domain
(DBD-D), and a C-terminal domain (RPA32C) largely involved in protein-protein interactions (12–14). RPA14 is referred to as DBD-E. All
the DBDs in RPA have similar structures built around a central oligosaccharide/oligonucleotide binding fold (6, 7, 11, 12, 15). However, the
N-terminal domain of RPA70 (also referred to as DBD-F or RPA70N)
has only been implicated in protein-protein interactions in DNA
metabolism (1–3, 6). In contrast, DBD-E (RPA14) shows no binding
affinity for ssDNA but is structurally important for the formation of
RPA trimerization core (11, 12). Slight differences in structure and residue compositions of the binding clefts of the DBDs may explain their
differences in ssDNA binding (16, 17).
It has been reported that the N-terminal domain of RPA32 (RPA32N)
becomes phosphorylated in a cell cycle-dependent manner (18 –20) and
hyperphosphorylated in response to DNA damage (21–24). The cell
cycle-dependent phosphorylation is carried out by cyclin-dependent
kinases and occurs at two consensus sites, Ser-23 and Ser-29, of RPA32
(19, 22, 25). More sites in RPA32N are phosphorylated in cells in
response to DNA damage (22, 23, 26) or apoptosis (27). Phosphopeptide
mapping has shown that at least five sites of RPA32N, including Thr-21,
Ser-23, Ser-29, Ser-33, and either Ser-11, -12, or -13 and probably two
additional sites, Ser-4 and Ser-8, can be phosphorylated in UV-irradiated HeLa cells (22, 25, 28). The DNA damage-induced hyperphosphorylation of RPA32 is believed to be carried out by the members of phosphatidylinositol 3-kinase-like serine/threonine protein kinase family,
which includes DNA-dependent protein kinase (DNA-PK), ataxia-telangiectasia mutated kinase (ATM), and ATM- and Rad3-related kinase
(ATR) (2, 4, 23, 24, 29 –31). DNA-PK phosphorylates RPA32 in vitro at
many of the same sites that are phosphorylated in vivo in HeLa cells after
UV irradiation (22, 24, 25).
One of the most striking aspects of RPA is that the protein is involved
in almost all DNA metabolic pathways in cells. It is believed that such
broad cellular activities of RPA are mediated by its interactions with
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ssDNA and numerous proteins engaged in cellular processes (9, 14).
RPA phosphorylation may play a role in regulation of these interactions
and, thus, the cellular functions of RPA (24). It has been shown that RPA
hyperphosphorylation down-regulates DNA replication (24, 32). In particular, hyperphosphorylation of RPA32 may modulate RPA interactions with DNA and proteins involved in the DNA repair and signaling
pathways in response to DNA damage (2, 24). For instance, hyperphosphorylated RPA (hyp-RPA) has shown decreased interactions with simian virus 40 (SV40) T antigen, DNA polymerase ␣, DNA-PK, ATM, and
p53, whereas hyperphosphorylation has no effects on RPA interactions
with XPA, Rad51, and Rad52 (20, 24, 33–37). In addition, hyp-RPA
binds double-stranded DNA with a reduced affinity (20, 38), whereas
the effects of hyperphosphorylation on RPA interaction with ssDNA
remain controversial (20, 38, 39). Despite the significant role of hyperphosphorylation of RPA in modulating its cellular functions, the biochemical basis of the effects is still poorly understood. A possible scenario is that RPA may change its structure or conformation upon
hyperphosphorylation and, thus, alter the protein activities and functions. A synthetic peptide fragment with eight Ser/Thr residues substituted to Asp to mimic the hyperphosphorylated RPA32N was shown to
interact with DBD-F (RPA70N) fragment (RPA701–168) (38). However,
the structural characteristics of the hyperphosphorylated RPA trimer of
full-length remain to be elucidated.
In the present study we determined the hyperphosphorylation-dependent structural alterations of human RPA protein using mass spectrometric protein footprinting, limited proteolysis, and tryptophan fluorescence spectroscopy. Of 42 basic residues readily susceptible to
modification with small chemical reagents in the native protein, the
three amino acids Lys-343, Arg-335, and Arg-382 in DBD-B of RPA70
were shielded in the context of the hyperphosphorylated RPA. Our
results indicate that these residues were exclusively involved in a limited
structural alteration of the protein upon hyperphosphorylation of the
RPA32 N terminus. In particular, this local structural change showed
effects on the RPA interactions with 8-mer ssDNA or partial DNA
duplexes containing ssDNA tails. Considering the essential role of RPA
in most of cellular DNA metabolic processes including those mediated
with short ssDNA-associated partial DNA duplexes, our results provide
the biochemical basis for the roles of hyperphosphorylation in regulation of RPA functions.

EXPERIMENTAL PROCEDURES
Protein Production and Purification—Recombinant human RPA was
expressed in Escherichia coli BL21(DE3)-RP cells harboring the plasmid
pTYB-RPA and purified as previously described (40). Two RPA
mutants, Trp-107/528 and Trp-212/361, which had all the tryptophans
of RPA replaced by phenylalanine except for residues 107 and 528 or
residues 212 and 361, were expressed from BL21(DE3)-RP cells containing the plasmids constructed by site-directed mutagenesis. The mutant
proteins were purified by the same procedures as for native RPA.
In Vitro Phosphorylation by DNA-PK—For hyperphosphorylation,
the purified RPA or mutants were incubated with DNA-PK isolated
from HeLa nuclear extracts as a complex consisting of a 400-kDa catalytic subunit and the DNA binding component of 85- and 70-kDa Ku
subunits (Promega) at 30 °C for 30 min in the phosphorylation buffer
(40 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM DTT, 200 M ATP, and 10
g/ml calf thymus DNA). A mock treatment of proteins was carried out
in parallel under the exact same conditions except that no ATP was
added in the phosphorylation buffer. The reaction mixtures were then
loaded onto an HR10/30 Superdex 200 column equipped with an AKTA
purifier system (Amersham Biosciences). To purify the hyperphosphorylated RPA, the column was pre-equilibrated with the fast protein liq-
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uid chromatography running buffer containing high concentrations of
salt (40 mM HEPES, pH 7.5, 2 M NaCl, 10 mM MgCl2, 10 M ZnCl2, and
1 mM DTT) and run with the same buffer at 4 °C. The fractions containing hyperphosphorylated proteins or mock-treated proteins were
pooled and dialyzed against RPA storage buffer (40 mM HEPES, pH 7.5,
50 mM NaCl, 10 mM MgCl2, 10 M ZnCl2, 1 mM DTT, and 50% glycerol).
Protein concentration was determined using Bio-Rad protein assay kit.
Chemical Modification and In-gel Proteolysis—Biotinylation of lysine
residues of RPA was carried out as described previously (41). Briefly, 2
M hyp-RPA or RPA was incubated with N-hydroxysuccinimidobiotin
(NHS-biotin, Pierce) in 50 mM HEPES, pH 7.5, 50 mM NaCl at 25 °C for
30 min. The reactions were then quenched by the addition of 10 mM
lysine. The three subunits of RPA were separated by SDS-PAGE and
visualized by Coomassie Blue stain. The corresponding bands were
excised, and the gel slices were destained, dehydrated, and digested with
1 g of trypsin (Roche Applied Science) in 50 mM NH4HCO3 at 25 °C
overnight. Proteolytic peptides were recovered and subjected to MS and
MS/MS analysis.
Modification of arginine residues was performed by incubating 2 M
hyp-RPA or RPA with p-hydroxyphenylglyoxal (HPG, Pierce) in 50 mM
HEPES/50 mM boric acid, pH 8.0, at 37 °C in the dark for 60 min. The
modification was quenched by the addition of 100 mM arginine. Then
samples were subjected to SDS-PAGE, and protein bands were excised
and processed as described above.
MS and MS/MS Analysis—MS spectra were obtained using matrixassisted laser desorption time of flight (MALDI-TOF) and quadrupoletime of flight (Q-TOF) techniques. MALDI-TOF experiments were
performed using a Kratos Axima-CRF instrument (Kratos Analytical
Instruments) with ␣-cyano-4-hydroxycinnamic acid matrix. MS and
MS/MS analyses were performed on a Micromass (Manchester, UK)
Q-TOF-II instrument equipped with an electrospray source and Micromass cap-LC. Peptides were separated with a Waters Symmetry300
5-m precolumn (Waters, Milford, MA) and a Micro-Tech Scientific
(Vista, CA) ZC-10-C18SBWX-150 column using two sequential gradients of 5– 40% acetonitrile for 35 min and 40 –90% acetonitrile for 20
min. MS/MS sequence data and the MASCOT automated peptide
search engine (www.matrixscience.com) were used to identify RPA
peptide peaks from the NCBInr primary sequence data base, and
matched peaks were then located in the primary MS spectra. Protection
events were qualitatively assigned as the appearance of a peak corresponding to a modified peptide in the modified protein spectrum and
the absence of the modification peak in the modified hyperphosphorylated protein spectrum. A protection was considered to be significant
only when the intensity of a modifiable peak was reduced by at least 85%
in the hyp-RPA spectrum. To accurately identify protection events, at
least two unmodified proteolytic peptide peaks present in all four spectra (unmodified protein, modified protein, unmodified hyp-protein, and
modified hyp-protein) were used as controls. These control peaks
served to standardize the peak intensities in each spectrum for accurate
qualitative assignment of protection. Data were reproducibly compiled
and analyzed from six independent experimental groups.
Fluorescence Spectroscopy Determination—The tryptophan fluorescence spectra of RPA, its mutants, and their hyperphosphorylated forms
were recorded on a SPEX Fluorolog-3 fluorometer (Jobin Yvon, Inc.)
with the excitation wavelength at 295 nm and the slit widths set at 3 nm
for excitation and 5 nm for emission beams. After equilibration of 100
nM protein in RPA buffer (40 mM HEPES-KOH, pH 7.9, 75 mM KCl, 8
mM MgCl2, 1 mM DTT, and 5% glycerol) at 25 °C for 10 min, the fluorescence spectra were obtained by recording emission from 310 to 500
nm. For the constant wavelength analysis, the emission at 355 nm was
measured with excitation at 295 nm.
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Fluorescence anisotropy measurements were performed to compare
the binding of RPA and hyp-RPA to an oligo(dT)8. The (dT)8 with a
fluorescein labeled at 5⬘ end was purchased from Qiagen in high performance liquid chromatography-purified quality. The anisotropy titrations were performed as described previously (42), and the data were
processed using a one-site binding model and the non-linear least
squares method for the determination of the binding constants (43).
Partial Proteolysis and Identification of Proteolytic Fragments— 4 g
of recombinant human RPA or hyp-RPA was incubated with chymotrypsin (1:80) at room temperature for the indicated periods in a reaction buffer (10 l) containing 40 mM HEPES, pH 7.8, 1 mM EDTA, 70
mM MgCl2, and 10 mM DTT. At each time point (5, 20, or 60 min), 2.5 l
of the reaction mixture was removed and terminated by the addition of
Laemmli sample buffer and boiling for 10 min. The proteolytic products
were resolved by 14% SDS-PAGE and stained with SYPRO Ruby protein
gel stain (Bio-Rad). After destained with a solution containing 10%
methanol and 7% acetic acid, the gel was imaged by phosphorimaging
(FLA-5000, FUJIFILM) using a 473-nm laser line. For automated N-terminal sequencing, the proteolytic fragments separated on the 14% SDSPAGE were transferred to a polyvinylidene difluoride membrane followed by staining with Coomassie Brilliant Blue G-250. The protein
bands of interest were excised and sent to the protein chemistry laboratory at the University of Texas Medical Branch for sequencing.
Gel Mobility Shift Assays —ssDNA was radiolabeled with [␥-32P]ATP
and T4 polynucleotide kinase. The labeled substrate (1 nM) was then
incubated with the indicated amounts of hyp-RPA or RPA at room
temperature for 15 min in 20 l of the binding buffer (40 mM HEPESKOH, pH 7.9, 75 mM KCl, 8 mM MgCl2, 1 mM DTT, 5% glycerol, and 100
g/ml bovine serum albumin). After incubation, 2 l of 80% (v/v) glycerol was added, and the mixture was immediately loaded onto a 4%
native polyacrylamide gel in 1⫻ TBE running buffer (89 mM Tris borate
and 2 mM EDTA, pH 8.3) and electrophoresed at room temperature.
The gel was then dried. The free and bound DNA was visualized using a
PhosphorImager (FLA-5000, FUJIFILM).
Pull-down Assays—The binding of RPA to partial DNA duplexes
containing 5⬘-protruding 11 nucleotides (DNA-11) or 3⬘-protruding 10
nucleotides (DNA-10) were investigated by a streptavidin-agarose pulldown assay. The sequences of the oligonucleotides used to construct the
partial DNA duplexes are as follows: 55-mer, Biotin-GGACCTGAACACGTACGGAATTCGATATCCTCGAGCCAGATCTGCGCC AGCTGGC; 44-mer, GCCAGCTGGCGCAGATCTGGCTCGAGGATATCGAATTCCG TACG; 45-mer, GCAGATCTGGCTCGAGGATATCGAATTCCGTACGTGTTCAGGT CC. The 44- and 45-mer were
5⬘-32P-labeled and annealed to their complementary biotinylated
55-mer at a molar ratio of 1:1. The annealing mixture was then loaded
onto an 8% native polyacrylamide gel in 1⫻ TBE running buffer and
electrophoresed at 80 V for 3 h at room temperature. Using the 5⬘-32Plabeled 44-, 45-, and 55-mer as controls, the bands identified as the
partial DNA duplexes, which migrated slower than the single-stranded
oligonucleotides in the gel, were excised, eluted, and precipitated with
ethanol. After the purification 5 pmol of the partial DNA duplex were
incubated with the indicated amounts of mixed hyp-RPA and RPA in
500 l of the binding buffer at room temperature for 15 min. Then 20 l
of streptavidin-conjugated agarose beads (Invitrogen) pre-washed with
the binding buffer was added. The mixture was placed on a rotating
shaker with gentle mixing at room temperature for 30 min. The beads
were collected by centrifugation and washed 3 times with the binding
buffer. The proteins in the complex were assessed by Western blotting
using an antibody specific for RPA32 as described below.
Western Blotting—Protein samples were separated by 10% SDSPAGE and transferred to a polyvinylidene difluoride membrane in Tris-
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FIGURE 1. In vitro phosphorylation of RPA by DNA-PK. A, the phosphorylation reaction
was conducted as described under “Experimental Procedures.” Proteins including
untreated RPA (lane 1), mock-treated RPA (lane 2), hyp-RPA (lane 3), and calf intestinal
phosphatase (CIP)-treated hyp-RPA (lane 4) were visualized by 14% SDS-PAGE and Coomassie Blue staining. B, immunoblot of RPA hyperphosphorylated by DNA-PK (lane 1),
RPA (lane 2), and RPA in UV-irradiated HeLa cells (lane 3). To prepare the RPA in UVirradiated HeLa cells, whole cell lysates were prepared from HeLa cells at 8 h after irradiation with 20 J/m2 UV. Proteins were separated on a 10% SDS-PAGE followed by Western
blotting using an antibody specific for RPA32.

glycine buffer (0.375 M Tris, 0.192 M glycine, 20% methanol). The membrane was blocked with 5% nonfat milk at room temperature for 1 h and
then treated with a monoclonal anti-RPA32 antibody (Kamiya Biomedical) at 0.5 g/ml in phosphate-buffered saline supplemented with 5%
nonfat milk at 4 °C overnight with shaking. The RPA32 protein bands
were visualized using anti-mouse IgG conjugated with horseradish peroxidase as the secondary antibody (Santa Cruz) by following the protocol of the ECL Western blotting System (Amersham Biosciences).

RESULTS
In Vitro Hyperphosphorylation of RPA by DNA-PK—It has been well
established that DNA-PK is involved in the DNA damage-induced RPA
hyperphosphorylation in cells (23, 29 –31, 39, 44 – 46). DNA-PK is composed of the Ku70/80 heterodimer and the catalytic subunit DNA-PKcs
(47). The sites of RPA phosphorylated by DNA-PK in vitro are similar to
those phosphorylated in vivo after UV irradiation of human cells (22,
25). Although RPA may also be hyperphosphorylated by other phosphatidylinositol 3-kinase-like serine/threonine protein kinase family
members such as ATR and ATM in response to DNA damage in vivo,
hyperphosphorylation of RPA by DNA-PK represents a typical one for
study of the DNA damage-induced RPA hyperphosphorylation. To
investigate the changes of RPA structure and activity upon hyperphosphorylation, we prepared the hyperphosphorylated RPA by incubating
purified recombinant RPA with DNA-PK in the presence of calf thymus
DNA (Promega). After a hyperphosphorylation reaction, the RPA (116
kDa) was separated from DNA-PK (three subunits: 400, 80, and 85 kDa)
and DNA by gel filtration with the running buffer containing 2 M NaCl
followed by dialysis against RPA storage buffer. A high salt concentration was used to dissociate RPA from the kinase and DNA, whereas the
RPA remained in the form of trimer (Fig. 1A). The SDS-PAGE and
Western blotting analyses of the RPA hyperphosphorylation showed
that more than 85% of RPA32 was hyperphosphorylated by DNA-PK, as
indicated by the band shifted from the native RPA32 (Fig. 1, A, lane 3,
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TABLE ONE

Identification of modified lysines or arginines in RPA and hyp-RPA
The residues that were protected from modification in hyper-RPA are indicated in bold and underlined.
RPA subunits
Biotin-modified lysines
RPA70
RPA32
RPA14

88, 163, 167, 183, 206, 220, 244, 263, 259, 324,
331, 343, 379, 489, 502, 577, 588, 595
38, 93, 138, 139
33, 49

HPG-modified arginines

91, 92, 202, 210, 216, 335, 382, 472, 573, 575,
586, 600, 604, 605, 611
40, 133
30

FIGURE 2. Mass spectrometric analysis of relative reactivity of lysines in RPA and hyp-RPA
with NHS-biotin. A, representative segment of
MALDI-TOF data showing that Lys-343 was readily
biotinylated in native RPA and not in hyp-RPA. B,
MALDI-TOF data illustrate the biotinylated peptide peaks (amino acids 373–382 and 82–91) were
unchanged in RPA and hyp-RPA. C1-C5 were control peaks that serve as references for peak intensity. C, MS/MS analysis of the doubly charged ion
414.70 representing the modified peptide amino
acids 340 –344 with a Q-TOF instrument reveals
biotinylated Lys-344. The left panel shows doubly
charged parent ions; the right panel shows fragmentation results.
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FIGURE 3. MALDI-TOF analysis of relative reactivity of arginines in RPA and hyp-RPA
with HPG. A, representative segment of mass spectra showing that Arg-335 and Arg-382
in RPA70 were readily modified with HPG in native protein but were significantly protected from the modification in hyper-RPA. B, control data demonstrating that the peak
corresponding to the peptide (128 –138) with Arg-133 modified by HPG in RPA32 of RPA
and hyp-RPA remained unchanged. Unmodified peptide peaks C6 and C7 serve as references for peak intensity.

and B, lane 1). And this phosphorylation was fully reversed after the
treatment of the hyp-RPA with calf intestinal phosphatase as the retardation was diminished (Fig. 1A, lane 4). No phosphorylation by
DNA-PK was observed in RPA70 and RPA14 subunits, as confirmed by
the ents with [␥-32P]ATP (data not shown), which is also in agreement
with that of a previous report (48). It has been generally known that in
vivo phosphorylation results in five isoforms of RPA, which represent
different levels of phosphorylation as indicated by the mobility shifts of
RPA32 on SDS-PAGE (20 –22, 49) (Fig. 1B, lane 3). Of them, forms 2–3
occur in a cell cycle-dependent manner, whereas forms 4 –5 are the
hyperphosphorylated RPA32 and appear upon cellular DNA damage.
Comparison of RPAs phosphorylated in vitro and in vivo by Western
blotting revealed that most of the DNA-PK-hyperphosphorylated RPA
had the same mobility shifts as did forms 4 and 5 of RPA from UVirradiated HeLa cells.
Surface Topology Analysis of Native and Hyperphosphorylated RPAs
with Group-specific Reagents and Mass Spectrometry—Chemical modifications coupled with mass spectrometry have been used to probe the
surface topology of proteins (50 –52). Recently, a strategy of protein
footprinting has been developed by Kvaratskhelia et al. (53) for accurate
mapping of protein-nucleic acid interactions using mass spectrometry.
Here we extend this method to probe conformational changes of RPA
after hyperphosphorylation by monitoring the changes of surface accessibility of lysine and arginine residues susceptible to NHS-biotin and
hydroxyphenylglyoxal (HPG) modifications, respectively. Comparison
of surface topologies of native and hyperphosphorylated RPAs would
enable us to identify conformational changes in the full-length protein
induced by hyperphosphorylation.
Of note, maintenance of the structural integrity of proteins under the
modification conditions is crucial for the success of these experiments.
Therefore, we optimized concentrations of NHS-biotin and HPG. Our
recent work indicated that upon treatment of the RPA-ssDNA complex
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with 400 M NHS-biotin, the integrity of nucleoprotein complex was
fully preserved (41). Therefore, in the present study we employed the
same reaction conditions. A similar approach was used to optimize the
HPG modification. We found that integrity of RPA-ssDNA complex
was fully preserved with treatment of 1.25 mM HPG and employed this
concentration in the present study.
NHS-biotin reacts specifically with primary amines on the surface of
proteins, resulting in covalent addition of a biotin molecule (226 daltons) to lysine and release of an N-hydroxysuccinimide (53). The modified residues could be readily identified with subsequent MS and
MS/MS analysis of the proteolytic fragments. We have recently
reported an NHS-biotin modification pattern of the full-length RPA and
RPA-ssDNA complex (41). In the present study we compared the biotinylation sites of the native and hyp-RPA proteins by MALDI-TOF. A
total of 24 biotinylated tryptic peptides were identified for native RPA
including 18 fragments from RPA70, 4 from RPA32, and 2 from RPA14
(TABLE ONE). The biotinylation patterns and intensities of the biotinylated peptides were almost identical between the native and hypRPA proteins, except that of the biotinylated peptide of amino acids
340 –344 of DBD-B (Fig. 2). This peptide peak was readily detectable in
the MS spectra of native RPA but was significantly diminished in hypRPA (Fig. 2A). Fig. 2B is a representative segment of MALDI-TOF spectra showing that Lys-88 and Lys-379, two others of the 24 modified
lysines, were biotinylated equally well in both native and hyp-RPA proteins. MS/MS analysis of the amino acids 340 –344 peptide peak, which
exhibited protection in the context of hyp-RPA, indicated the biotinylation of Lys-343 (Fig. 2C). Given that 23 modified lysines distributed on
the surfaces of almost all the domains of RPA trimer, the exhibited
similar modification patterns in native and hyp-RPA suggest that no
significant global conformational changes occurred in RPA after hyperphosphorylation. However, the inaccessibility of residue Lys-343 of
RPA70 to NHS-biotin modification in hyp-RPA suggested occurrence
of a limited structural re-arrangement involving the DBD-B domain
containing Lys-343 and the hyperphosphorylated N terminus of RPA32.
Because Lys-343 is located in the DNA binding cleft of DBD-B, adjacent
to the L12 loop (amino acids 330 –342), it is possible that the hyperphosphorylation resulted in at least partial shielding of the binding cleft of
DBD-B from biotinylation via intramolecular interactions.
We next examined the arginine modifications of RPA and hyp-RPA
with HPG. HPG reacts specifically with the guanidyl group of arginine
under mild conditions (pH 7–9, 25 °C), resulting in the addition of a
mass of 131 daltons to the modified molecule (54). We observed modification of 18 arginines in the context of native RPA, of which 16 residues were identically susceptible to modification in hyper-RPA (TABLE
ONE). However, the following two peptide peaks, amino acids 332–339
(Arg-335 ⫹ HPG) and amino acids 380 –389 (Arg-382 ⫹ HPG) of
RPA70, were significantly diminished in hyper-RPA (Fig. 3A). Fig. 3B
depicts representative segments of MALDI-TOF spectra to show equal
intensities of mass signal for the modifications at Arg-133 of RPA32 in
both RPA and hyp-RPA. Residue Arg-335 is located in the L12 loop of
DBD-B, whereas Arg-382 is at the edge of the DNA binding cleft of
DBD-B, adjacent to L45 (7, 15). These results are fully consistent with
those of biotinylation studies above.
Fluorescence Measurements—RPA has eight tryptophan residues.
The locations of the tryptophans are shown in Fig. 4A: Trp-197 and
Trp-212 in DBD-A, Trp-361 and Trp-414 in DBD-B, Trp-442 and Trp528 in DBD-C, Trp-107 in DBD-D, and Trp-2 in the unstructured
RPA32N. Trp-212 and Trp-361 have been shown to be located in the
binding clefts of DBD-A and DBD-B, respectively, and to be involved in
the interactions with ssDNA (7). Trp-528 and Trp-107 are located in the
putative binding clefts of DBD-C and DBD-D, respectively, and were
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FIGURE 4. Measurements of the intrinsic fluorescence of tryptophans of RPA and its mutants. A, structural exhibition of the tryptophans in RPA. The DBDs (16, 18, 21) are
positioned by projecting the ssDNA binding clefts or the putative clefts in the same direction. The tryptophans of each DBD are marked. B, binding of RPA and its mutants to
oligo(dT)30. RPA or the mutants were incubated with 1 nM dT30 at increasing concentrations at 25 °C for 15 min in 20 l of the binding buffer. The binding products were analyzed on
a 4% native polyacrylamide gel. The positions of the bound and free oligonucleotides are indicated. C, emission spectra of RPA, its mutants, and their hyperphosphorylated forms. The
tryptophan fluorescence of the proteins (100 nM) was recorded from 310 to 500 nm at 25 °C with excitation at 295 nm in 200 l of RPA buffer. The slit widths were set at 3 and 5 nm
for excitation and emission beams, respectively. D, constant wavelength analyses of RPA, its mutants, and their hyperphosphorylated forms. The intensity of tryptophan fluorescence
of the proteins (100 nM) was recorded at 25 °C with excitation at 295 nm and emission at 355 nm in 200 l of RPA buffer. Three data points with an integration time of 5 s and S.E. of
0.5% were collected for each measurement. Three measurements for each sample were performed independently.

predicted to interact with ssDNA (11, 12). Indeed, we previously found
that the intrinsic fluorescence of all these in-cleft tryptophans were
quenchable upon ssDNA binding to RPA.3 If an intramolecular interaction involving any of the binding clefts occurs in hyp-RPA, the hyperphosphorylation could result in quenching of the tryptophan fluorescence in the clefts.
To dissect the roles of individual tryptophans in these interactions we
prepared the following two mutant proteins. The Trp-212/361 protein
was obtained by preserving these two tryptophans and replacing the
other 6 tryptophans with phenylalanines. Similarly, in the Trp-107/528
3

Y. Liu, M. Kvaratskhelia, S. Hess, Y. Qu, and Y. Zou, unpublished data.
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mutant the residues Trp-107 and Trp-528 were preserved, and the
other tryptophans were substituted with phenylalanines. The binding of
RPA mutants to ssDNA was tested to ensure that the mutants were
active. Fig. 4B shows that both mutants bound a dT30 with an affinity
comparable with that of native RPA, indicating that the substitutions of
tryptophans with phenylalanines had minimum effects on the binding
activity of RPA. Then these mutants together with wild type RPA were
subjected to a series of fluorescence measurements. As shown in Figs. 4,
C and D, the tryptophan fluorescence of the wild type RPA decreased
upon hyperphosphorylation, suggesting that a structural re-arrangement in hyp-RPA occurred. However, no fluorescence changes were
observed for the Trp-107/528 mutant before and after hyperphospho-
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rylation. By contrast, about one-half of the fluorescence was quenched
for hyp-Trp-212/361 (Figs. 4, C and D), suggesting that one of the two
tryptophans was involved in the structural re-arrangement induced by
hyperphosphorylation. Given that Trp-361 is located in the proximity of
Lys-343 and Arg-335 residues that were inaccessible to small chemical
modifications in hyp-RPA, we propose that the fluorescence of Trp-361
was quenched due to the intramolecular interaction involving hyperphosphorylated RPA32N and binding cleft of DBD-B. The fluorescence
quenching for hyp-Trp-212/361 mutant was much more pronounced
than that for wild type RPA. This suggests that more tryptophans in wild
type RPA did not exhibit quenching upon hyperphosphorylation,
resulting in a higher fluorescence background for the wild type protein.
Limited Proteolysis of RPA and hyp-RPA—Partial proteolysis could be
employed for probing conformational changes of a protein upon ligand
binding or macromolecular interactions via domain mapping (55–57).
Because proteolytic cleavage sites are usually located in the linking
regions or loops between domains on the surface of a protein (58),
structural variation of the protein with domain rearrangement may
change the accessibility of some of the cleavage sites, resulting in altered
proteolytic profiles. Previously, proteolytic experiments were carried
out to show that RPA changed its conformation upon binding to ssDNA
(55, 56) or partial duplex DNA containing a 5⬘-protruding tail (56). Here
we employed this method to compare the domain structures of native
and hyperphosphorylated RPAs. The two proteins were partially
digested with the fixed amount of chymotrypsin for the indicated time
periods (Fig. 5). As shown in Fig. 5A, chymotrypsin digestion revealed
several peptide fragments that were more resistant in hyp-RPA compared with native RPA. Amino acid sequencing enabled us to determine
that all these fragments resulted from cleavages at the sites located
in/near DBD-A and DBD-C of RPA70 (Fig. 5B and TABLE TWO). In
other words, these fragments contain no cleavages in DBD-B. Taken
together, these partial hydrolysis data indicated that hyperphosphorylation of RPA32N led to conformational changes in RPA70 and relative
resistance of DBD-B to partial proteolysis, which is consistent with the
higher resolution results obtained from mass spectrometric footprinting and tryptophan fluorescence studies.
Binding of RPA and hyp-RPA to ssDNA and Partial DNA Duplex—
How the structural changes of RPA affect its activities may define the
role of RPA hyperphosphorylation in DNA metabolism. Our previous
study showed that the Lys-343 residue in DBD-B was directly involved
in the RPA interaction with ssDNA (41). Because the 8 –10-nt binding
mode of RPA-ssDNA interaction has been suggested to be important
for the initiation of replication, replication lagging strand synthesis, and
nucleotide excision repair (2, 59), here we examined the binding of
hyp-RPA and RPA to an oligo(dT)8 by gel mobility shift assays (Fig. 6A)
and fluorescence anisotropy measurements (Fig. 6B). Both assays
revealed that hyp-RPA had a lower affinity for the (dT)8 compared with
the native RPA. The anisotropy data were best fitted using a one-site
binding model as described previously (42), and the resulting dissociation constants were 28.9 ⫾ 3.3 and 60.8 ⫾ 3.1 nM for native and hypRPAs, respectively. To test whether this affinity change was specific to DNA
sequence, an 8-mer ssDNA with random sequences (CATCCTAC) also
was used in our binding assays. Our results indicated similar reduction of
the biding affinity for this DNA species (data not shown).
To examine how hyp-RPA changes its interaction with physiologically relevant DNA substrates, a set of partial DNA duplexes that mimic
in vivo intermediates which occur during DNA replication and DNA
repair was subject to the binding assays. For this purpose, partial DNA
duplexes containing 5⬘-protruding 11 nucleotides (DNA-11) or 3⬘-protruding 10 nucleotides (DNA-10) were constructed. Fig. 6C shows the
binding of a mixture of hyp-RPA and RPA to biotin-labeled DNA-11
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FIGURE 5. Partial proteolysis of RPA and hyp-RPA with chymotrypsin. A, 4 g of RPA
or hyp-RPA was digested with chymotrypsin (1:80) at room temperature for the times
indicated. The reactions were then terminated, resolved by 14% SDS-PAGE, and visualized using SYPRO Ruby stain. Untreated RPA and hyp-RPA were loaded as controls (the
lanes marked as C). The molecular mass markers are shown on the left. Designations of
individual fragments (dashes) and RPA subunits (arrows) are marked on the right. B,
schematic map of proteolytic peptides generated upon RPA or hyp-RPA treatment with
chymotrypsin. Domains are presented as boxes. The cleavage sites of chymotryptic peptide fragments are roughly shown.
TABLE TWO

Identification of peptides of RPA or hyp-RPA digested by
chymotrypsin
Peptide
fragment

Size

N-terminal
sequence

Origin

kDa

1

51

RPA70

166

GKAAG (major)a
GASKT (minor)a
213
SNSRG
166
GKAAG
166
GKAAG
166
GKAAG (major)a
160
GASKT (minor)a
160

2
3
4
5
a

46
36
34
20

RPA70
RPA70
RPA70
RPA70

N-terminal sequencing gave two different sequences corresponding to two peptide
fragments that migrated at the same position on SDS-PAGE. The amount of one
peptide (major) was larger than the other (minor).

and DNA-10, as analyzed by the pull-down assay with streptavidinagarose and by Western blotting with an antibody against RPA32. The
pull-down assay allowed the binding of RPA and hyp-RPA to ssDNA to
be monitored simultaneously and individually as the two forms of RPA
protein were well separated on the SDS-PAGE. Thus, the binding of
native RPA to ssDNA could serve as an internal control for determination of relative ssDNA binding efficiency of hyp-RPA. As shown in Fig.
6C, the hyperphosphorylation led to a significant decrease in binding of
RPA to the DNA-11 and DNA-10 substrates by about 70 and 50%,
respectively, demonstrating that hyp-RPA had significantly lower affinity for these partial DNA duplexes than native RPA.

DISCUSSION
As a single-stranded DNA-binding protein in eukaryotic cells, RPA
interacts with a large variety of proteins required for DNA replication,
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FIGURE 7. DBD-B structure (15) with highlighted residues. Arg-335, Lys-343, Trp-361,
and Arg-382 are in brown that could directly interact with hyperphosphorylated
RPA32N. Two loops, Leu-12 and Leu-45, are indicated in blue.

FIGURE 6. Binding of RPA and hyp-RPA to oligo(dT)8 and partial DNA duplexes. A,
RPA was incubated with 1 nM (dT)8 at different molar ratios at 25 °C for 15 min in 20 l of
the binding buffer. The binding products were analyzed on a 4% native polyacrylamide
gel. The positions of bound (dT)8 and free (dT)8 are indicated. B, 10 nM (dT)8 with a
fluorescein labeled at 5⬘ end was titrated with RPA or hyp-RPA. The anisotropy was
measured at 520 nm with excitation at 492 nm. The binding isotherms were best fitted to
obtain the equilibrium dissociation constants (Kd,obs). C, binding of RPA and hyp-RPA to
partial DNA duplexes containing 5⬘-protruding 11 nucleotides (DNA-11, left) or 3⬘-protruding 10 nucleotides (DNA-10, right). DNA-11 and DNA-10 were constructed by
annealing a biotinylated 55-mer with its complementary 44- and 45-mer, respectively.
The biotinylated partial DNA duplex was incubated with a mixture of RPA and hyp-RPA.
The protein bound to DNA was pulled down with streptavidin beads and detected by
immunoblotting using an antibody against RPA32. The ratio of hyp-RPA to RPA in each
binding was quantified.

repair, recombination, and DNA damage checkpoints, suggesting that
RPA may play a regulatory role in the cellular DNA metabolic processes
(2, 24). In response to DNA damage, RPA undergoes hyperphosphorylation in cells carried out by the protein kinases of phosphatidylinositol
3-kinase-like serine/threonine protein kinase family (24). The hyperphosphorylation may play a role in modulating the cellular activities of
RPA via altering RPA ability to interact with DNA and proteins and is
critical to the success of cellular responses to genotoxic stresses. In the
present study we characterized the structural alterations of RPA upon
hyperphosphorylation by DNA-PK. Our findings provide new and
important structural information regarding the structural changes
introduced in the full-length PRA trimer upon hyperphosphorylation of
the protein.
Our mass spectrometric footprinting indicated that several basic residues were surface-inaccessible in DBD-B of RPA70 upon hyperphosphorylation of RPA32N. Tryptophan fluorescence studies suggested
that Trp-361 located in DBD-B was significantly quenched in response
to hyperphosphorylation. Limited proteolysis revealed structural
changes in RPA70 and the relative resistance of DBD-B to the proteo-

32782 JOURNAL OF BIOLOGICAL CHEMISTRY

lytic digestion upon phosphorylation of RPA32N. Taken together, our
findings suggest that a structural re-arrangement involving the RPA32N
and a number of residues in the ssDNA binding cleft of DBD-B occurs
after hyperphosphorylation of RPA (Fig. 7). Given that the N terminus
of RPA32 becomes highly acidic (pI was estimated to be around 2) upon
hyperphosphorylation, we propose that this structurally flexible protein
segment of 40 residues could then be electrostatically attracted to the
more positively charged basic region in the DNA binding cleft of
DBD-B. This is supported by an estimation that the fragment amino
acids 330 –345 in the DNA binding cleft of DBD-B, where Lys-343 and
Arg-335 were located, was more basic (pI ⬃ 12) than the equivalent
regions of other DBDs. It is obvious, however, that direct evidence is
needed to confirm the interdomain interaction of hyperphosphorylated
RPA32N with DBD-B in future studies.
A previous NMR study showed that a synthesized acidic peptide
mimicking hyperphosphorylated RPA32N was able to establish electrostatic interactions with the basic cleft of the purified DBD-F (RPA70N)
domain fragment (RPA701–168). However, in the study protein fragments rather than the full-length RPA trimer were used (38). In the
context of the full-length protein it is feasible that DBD-B is in the better
spatial setting with RPA32N than DBD-F. Indeed, based on the direction of the backbone at amino acid 45 of RPA32 in a crystal structure of
RPA trimerization core (DBD-C/DBD-D/RPA14), unphosphorylated
RPA32N was predicted to be located in the vicinity of the putative
ssDNA binding cleft of DBD-C (11). RPA32N in this position is closer to
DBD-B than to DBD-F, and thus, hyperphosphorylation of RPA32N is
more likely to have effects on the closely positioned DBD-B rather than
on the more distant DBD-F.
A possible immediate effect of the hyperphosphorylation-induced
protection of the ssDNA binding cleft of DBD-B from molecular access
on RPA function was the inhibition of RPA binding to ssDNA, particularly short ssDNA. Indeed, we observed that hyperphosphorylation of
RPA could affect the ability of the protein to bind short oligonucleotides. It has been generally accepted that RPA binds to ssDNA in three
modes in terms of the ssDNA lengths, 8 –10, 13–22, and 30 nt (2, 11). Of
these modes, the binding to 8 –10-nt (2, 7, 11, 60) or short ssDNA tails of
partial DNA duplexes (56, 61, 62) were exclusively carried out by
DBD-A and DBD-B, whereas the other two modes required the involvement of additional domains, DBD-C and DBD-C/DBD-D. Our results
suggest that the potential intramolecular interaction induced by
RPA32N hyperphosphorylation may compete with ssDNA binding to
DBD-B. Such competition may provide a regulatory mechanism for
modulating the RPA activities. However, the effect of the hyperphosphorylation of RPA appeared to be limited to the short ssDNA binding.
It has been reported that the association constant for the interaction of
RPA with 10-nt or shorter oligonucleotides was on the order of 107 M⫺1,
whereas the association constant for the RPA interaction with ssDNAs
longer than 15 nt was on the order of 109 –10 M⫺1 (63). Because DBD-B
is believed to participate in all modes of ssDNA binding, it is likely that
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the 2–3-order higher affinity of RPA to longer ssDNA may allow DBD-B
to predominately bind ssDNA so that the effect of the hyperphosphorylation becomes minimal. Indeed, our results (data not shown) and also
those from others showed that the hyperphosphorylation had a negligible effect on the RPA binding to the ssDNA of 30 nt or longer lengths
(20, 38).
In contrast, our results indicate significant competition between
hyperphosphorylation-elicited DBD-B shielding and DBD-B binding to
(dT)8 or partial DNA duplexes with a short ssDNA tail. Such data suggest that the association constant for the possible intramolecular interaction causing DBD-B shielding could be on the order of 107 M⫺1. Interestingly, interactions of RPA with these short ssDNA or partial DNA
duplexes with short ssDNA tails were believed to play a role in the
initiation of DNA replication and replicative lagging strand synthesis (2,
38, 59, 64). Therefore, it is likely that the hyperphosphorylation of RPA
could disrupt this process. Consistently, Vassin et al. (32) recently
reported that a hyperphosphorylation-mimic RPA failed to associate
with replication centers in vivo. Similarly, the DBD-B-engaged intramolecular interactions of RPA due to the hyperphosphorylation in the N
terminus of RPA32 could also affect the RPA-protein interactions (with
association constants on the order of 107 M⫺1) involved in various DNA
metabolic pathways.
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